Tag:
Enbrel
Latest Headlines
Latest Headlines
Amgen pushes agenda for biosimilars on the FDA
The Thousand Oaks, CA-base drugmaker is one of 30 organizations on the docket today for the FDA's informal stakeholder meeting to discuss regulation of biosimilars.
FDA harps on risks of Pfizer's tofacitinib as panel looms
FDA staffers raised concerns about increased risks of malignant cancers--particularly lymphomas--and infections tied to the drug.
UPDATED: Pfizer, Amgen prepare to dissolve Enbrel partnership
Pfizer and Amgen are sorting out responsibilities, and people, over Enbrel.
Amgen aims for growth in bone drugs, overseas markets
Amgen's ( $AMGN ) incoming CEO has high hopes for this year. Now COO, Robert Bradway says he's looking for revenue growth in 2012, thanks in part to international expansion. Another driver: Sales of
UPDATED: Enbrel beats rivals in rheumatologist survey
With the market for rheumatoid arthritis meds set to soar, rheumatologists weighed in on the existing drugs that provide the best outcomes for patients--and Amgen's ( $AMGN ) Enbrel topped the list,
Amgen's new Enbrel patent could delay biosims for 17 years
Would-be Enbrel copycats, get out your handkerchiefs. Amgen ( $AMGN ) says it has a new patent protecting the blockbuster anti-inflammatory drug, which could protect it from generic rivals for another
Merck trumpets loaded late-stage pipeline, big biosimilar R&D plans
With Wall Street demanding increased pipeline productivity from drug giants, Merck ( $MRK ) showed analysts and others exactly what investors are getting from one of the largest research budgets in the
Pfizer's U.S. sales drop, emerging markets grow
Emerging markets sales helped boost Pfizer's third-quarter profits--and the $1.3 billion gain on its sale of Capsugel didn't hurt, either. The U.S.-based drugmaker beat analyst expectations for sales
Merck strikes $720M deal with Hanwha for generic Enbrel
Merck has its eye on gaining a piece of the multi-billion dollar market for etanercept ( Enbrel ). The pharma giant has landed a deal to develop and commercialize a knockoff version of Amgen's
Celgene posts impressive IIb data on psoriasis
One of Celgene's mid-stage drug prospects may be getting closer scrutiny from analysts now that it's turned in promising results in a mid-stage clinical trial for psoriasis. In the trial, 41 percent
